- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The study by Tabbutt et al. seems to show that the clearance in neonates and infants is higher than in children aged > 1 year, at 281 and 126 ml/min/kg respectively.
In children aged 3-16 years with supraventricular arrhythmias, a terminal half-life averaging 6.9 min (range 5.2 to 10.9 min) and a volume of distribution averaging 283 ml/kg have been described.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Supraventricular tachycardia, perioperative hypertension and arrhythmias |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Dyspnoea, cold extremities, provocation of congestive heart failure or hypoglycaemia (without symptoms: take care with diabetes patients) and nightmares.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications in children
Sinus bradycardia, AV block, hypotension, asthma and congestive heart failure.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Great caution is needed in concomitant use of verapamil (Isoptin) because of the risk of severe arrhythmia. Be aware of the possibility of brief blood pressure drops.
In children weighing < 15 kg, recovery after the medication is stopped takes longer – about 15 min. Drops in blood pressure of 10-15% can occur in young children.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Beta blocking agents, non-selective | ||
|---|---|---|
| C07AA05 | ||
| C07AA07 | ||
| Beta blocking agents, selective | ||
|---|---|---|
| C07AB03 | ||
| C07AB07 | ||
| C07AB02 | ||
| Alpha and beta blocking agents | ||
|---|---|---|
| C07AG02 | ||
| C07AG01 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Tabbutt S, et al, The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: a multicenter, double-blind, randomized trial, J Thorac Cardiovasc Surg, 2008, Aug;136(2), 321-8
- Adamson PC, et al, The pharmacokinetics of esmolol in pediatric subjects with supraventricular arrhythmias., Pediatr Cardiol, 2006, Jul-Aug;27(4), 420-7
- Wiest DB, et al, Esmolol for the management of pediatric hypertension after cardiac operations, J Thorac Cardiovasc Surg, 1998, Apr;115(4), 890-7
- Cuneo BF, et al, Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children, Pediatr Cardiol, 1994, Nov-Dec;15(6), 296-301
- Trippel DL, et al, Cardiovascular and antiarrhythmic effects of esmolol in children, J Pediatr, 1991, Jul;119(1 Pt 1), 142-7
- Wiest DB, et al, Pharmacokinetics of esmolol in children, Clin Pharmacol Ther, 1991, Jun;49(6), 618-23
- Lurbe E, et al, Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension, J Hypertens, 2009, Sep;27(9),, 1719-42
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
